Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

Core Viewpoint - Helix BioPharma Corp. has extended its Research and Exclusive Option Agreement with metaShape Pharma AG for the compound LEUMUNA™ until December 31, 2028, allowing further research and development in metabolic diseases while maintaining a focus on oncology assets [1][4]. Group 1: Agreement Details - The original agreement was established in April 2023 between metaShape and Laevoroc Immunology AG, granting metaShape an exclusive research license and an option for a commercial license for LEUMUNA™ [2]. - The extension of the agreement provides additional time to advance research activities and supports the progression of the program toward clinical-stage development [4]. Group 2: Compound Development - MS 001, the compound under development, is designed as an orally administered co-therapy to GLP-1 receptor agonists, aimed at enhancing adipose tissue reduction and weight loss durability [2]. - Preclinical studies indicated that MS 001 increased levels of inosine and NAD+, which improved mitochondrial function and energy expenditure in adipose tissue, leading to better weight loss outcomes in mice [3]. Group 3: Company Perspectives - The CEO of metaShape expressed excitement about the progress of MS 001 and the developments in the program [5]. - Helix's CEO highlighted the quality of preclinical data around MS 001, particularly its effects on NAD+ biology and fat metabolism, indicating potential benefits across various disease settings [5]. Group 4: Company Backgrounds - MetaShape Pharma, founded in 2023, focuses on developing first-in-class metabolic therapies to address metabolic dysfunction [6]. - Helix BioPharma specializes in oncology, with a pipeline that includes Tumor Defense Breaker™ L-DOS47 and two pre-IND candidates: LEUMUNA™ and GEMCEDA™, aimed at treating hard-to-treat cancers [7].